Résultats de la recherche - Akhteruzzaman Molla
- Résultat(s) 1 - 18 résultats de 18
-
1
-
2
-
3
Pathogenic capacity of proteases from Serratia marcescens and Pseudomonas aeruginosa and their suppression by chicken egg white ovomacroglobulin par Akhteruzzaman Molla, Yasuhiro Matsumura, Takashi Yamamoto, R Okamura, Hiroshi Maeda
Publié 1987Artigo -
4
-
5
Selection of Resistance in Protease Inhibitor-Experienced, Human Immunodeficiency Virus Type 1-Infected Subjects Failing Lopinavir- and Ritonavir-Based Therapy: Mutation Patterns a... par Hongmei Mo, Martin S. King, Kathryn King, Akhteruzzaman Molla, Scott Brun, Dale J. Kempf
Publié 2005Artigo -
6
-
7
Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System par Yupeng He, Martin S. King, Dale J. Kempf, Liangjun Lu, Hock Ben Lim, Preethi Krishnan, Warren M. Kati, Timothy Middleton, Akhteruzzaman Molla
Publié 2007Artigo -
8
Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro par Liangjun Lu, Edward Tam, Kent D. Stewart, John T. Randolph, Ron Pithawalla, Wenping He, Peggy Huang, Larry L. Klein, Hongmei Mo, Akhteruzzaman Molla
Publié 2004Artigo -
9
In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-378, a Novel Protease Inhibitor par Alejandro Vicente‐Carrillo, Kent D. Stewart, Hing L. Sham, Daniel W. Norbeck, William E. Kohlbrenner, John M. Leonard, Dale J. Kempf, Akhteruzzaman Molla
Publié 1998Artigo -
10
<i>In Vitro</i> Activity and Resistance Profile of Dasabuvir, a Nonnucleoside Hepatitis C Virus Polymerase Inhibitor par Warren M. Kati, Gennadiy Koev, Michelle Irvin, Jill Beyer, Yaya Liu, Preethi Krishnan, Thomas Reisch, Rubina Mondal, Rolf Wagner, Akhteruzzaman Molla, Clarence J. Maring, Christine A. Collins
Publié 2014Artigo -
11
The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir par Dale J. Kempf, Richard A. Rode, Yi Xu, Eugene Sun, Margo Heath‐Chiozzi, Joaquin Valdes, Anthony J. Japour, Sven Danner, Charles A. Boucher, Akhteruzzaman Molla, John M. Leonard
Publié 1998Artigo -
12
Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology par Teresa I. Ng, Hongmei Mo, Edward Tam, Yupeng He, Gennadiy Koev, Preethi Krishnan, Rubina Mondal, Ron Pithawalla, Wenping He, Tanya Dekhtyar, Jeremy C.L. Packer, Mark E. Schurdak, Akhteruzzaman Molla
Publié 2007Artigo -
13
In Vitro Characterization of A-315675, a Highly Potent Inhibitor of A and B Strain Influenza Virus Neuraminidases and Influenza Virus Replication par Warren M. Kati, Debra Montgomery, Robert J. Carrick, Larisa V. Gubareva, Clarence J. Maring, Keith F. McDaniel, Kevin Steffy, Akhteruzzaman Molla, Frederick G. Hayden, Dale J. Kempf, William E. Kohlbrenner
Publié 2002Artigo -
14
Human Serum Attenuates the Activity of Protease Inhibitors toward Wild-Type and Mutant Human Immunodeficiency Virus par Akhteruzzaman Molla, Sudthida Vasavanonda, Gondi Kumar, Hing L. Sham, Marianne K. Johnson, Brian Grabowski, Jon F. Denissen, William E. Kohlbrenner, Jacob J. Plattner, John M. Leonard, Daniel W. Norbeck, Dale J. Kempf
Publié 1998Artigo -
15
<i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A par Preethi Krishnan, Jill Beyer, Neeta Mistry, Gennadiy Koev, Thomas Reisch, David A. DeGoey, Warren M. Kati, Andrew Campbell, Laura A. Williams, Wangang Xie, Carolyn M. Setze, Akhteruzzaman Molla, Christine A. Collins, Edward Tam
Publié 2014Artigo -
16
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects par Ann Hsu, G. Richard Granneman, Galen Witt, C. Locke, Jon F. Denissen, Akhteruzzaman Molla, Joaquin Valdes, Jr. Smith, Keith Erdman, Nicholas A. Lyons, Ping Niu, J Decourt, J. B. Fourtillan, J. Girault, John M. Leonard
Publié 1997Artigo -
17
Mutations Conferring Resistance to a Hepatitis C Virus (HCV) RNA-Dependent RNA Polymerase Inhibitor Alone or in Combination with an HCV Serine Protease Inhibitor In Vitro par Hongmei Mo, Liangjun Lu, Edward Tam, Ron Pithawalla, Rubina Mondal, Sherie Masse, Tatyana Dekhtyar, Teresa I. Ng, Gennadiy Koev, Vincent S. Stoll, Kent D. Stewart, John K. Pratt, Pam Donner, Todd W. Rockway, Clarence J. Maring, Akhteruzzaman Molla
Publié 2005Artigo -
18
<i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450 par Edward Tam, Rakesh Tripathi, Daniel E. Cohen, I. Gaultier, Tatyana Dekhtyar, Liangjun Lu, Thomas Reisch, Michelle Irvin, Todd A. Hopkins, Ron Pithawalla, Timothy Middleton, Teresa I. Ng, Keith F. McDaniel, Yat Sun Or, Rajeev Menon, Dale J. Kempf, Akhteruzzaman Molla, Christine A. Collins
Publié 2014Artigo
Outils de recherche:
Sujets similaires
Biology
Gene
Virology
Biochemistry
Virus
Enzyme
Antiretroviral therapy
Genetics
Protease
Viral load
Hepatitis C virus
Molecular biology
Protease inhibitor (pharmacology)
RNA
Ritonavir
Hepacivirus
Plasmid
Replicon
Genotype
Medicine
Microbiology
NS3
Viral replication
Chemistry
Internal medicine
NS5B
Pharmacology
Dasabuvir
Drug resistance
Escherichia coli